Redlight Guide

Breast cancer-related lymphedema

Photobiomodulation for breast cancer-related lymphedema

Evidence for PBM/LLLT in breast cancer-related lymphedema, including swelling, pain, and quality-of-life outcomes.

Study count

Cited reviews include nine studies and a later regimen-focused meta-analysis.

Evidence grade

moderate

Panel relevance

not-panel-replicable

Bottom line

This is a strong medical PBM category but a poor consumer panel category.

Consensus: PBM/LLLT appears to reduce swelling and improve some symptoms in breast cancer-related lymphedema, but protocols are clinical and should be supervised.

What the studies found

  • A 2015 review found moderate-strength evidence for limb-volume reduction and clinically meaningful pain/volume changes after LLLT.
  • A 2023 review found axillary targeting, three-times-weekly treatment at 1.5-2 J/cm2, and more than 15 sessions favored some outcomes.
  • Long-term and large-scale evidence remains needed.

Dosage and timing

WavelengthsNot settled nm
IrradianceNot settled
FluenceOne regimen analysis favored 1.5-2 J/cm2.
Session timeClinical protocol-specific.
FrequencyThree times per week favored swelling outcomes in one analysis.
DurationMore than 15 sessions favored some outcomes.
TimingPost-cancer-treatment lymphedema management context.
Treatment areaAxilla and upper-limb lymphedema targets.
Device typesClinical low-level laser / PBM.
NotesLymphedema care should be integrated with oncology/rehab guidance.
  • Regimen evidence is more specific here than in many categories, but still clinical-device-specific.
  • Home panels should not be substituted for lymphedema therapy.
  • Protocol should be clinician-selected.

Caveats

  • Cancer-related lymphedema requires specialized care.
  • Do not imply PBM replaces compression, exercise, manual therapy, or oncology follow-up.

Cited peer-reviewed sources

meta-analysis 9 included studies Evidence: moderate; direction: positive Panel relevance: not-panel-replicable Wavelengths: Not reported Dose/timing: Clinical lymphedema protocol-specific / Varied by study Area: Upper limb/axillary lymphedema targets Device: Low-level laser therapy Source

Smoot B, Chiavola-Larson L, Lee J, et al. Journal of Cancer Survivorship. 2015.

A 2015 meta-analysis found moderate-strength evidence that LLLT reduced arm volume and pain in breast cancer-related lymphedema.

Source

meta-analysis Study count not extracted Evidence: low; direction: positive Panel relevance: not-panel-replicable Wavelengths: Not reported Dose/timing: 2 J/cm2 / Three times per week in the favored subgroup / More than 15 sessions favored some outcomes Area: Axilla or lymphedema-related upper limb targets Device: Low-level laser / photobiomodulation Source

Chiu ST, Lai UH, Huang YC, et al. Lasers in Medical Science. 2023.

A regimen-focused meta-analysis found PBM can reduce swelling and improve quality of life in breast cancer-related lymphedema, with better outcomes in some axillary protocols.

Source

Last reviewed: 2026-06-15